NGeneBio Co., Ltd.
KOSDAQ-listed precision-diagnostics company manufacturing genomic diagnostic reagents and developing related software.
Price
Change
Market cap
Business overview
Source: DART corporate disclosureFounded in 2015 and listed on KOSDAQ in 2020, NGeneBio is a precision-diagnostics company. It manufactures genomic diagnostic reagents. It also engages in the research, development, and sale of genomic software.
Products & technology
- Genomic diagnostic reagentsGenomic-based precision diagnostics
Regulatory approvals
data.go.kr12 Korean MFDS device approvals · 2017–2025
- MFDSIVD reagents for cancer related gene2025-03-28Product approval · Class 3체외 제허 25-197 호
- MFDSIVD reagents for cancer related gene2025-02-25Product approval · Class 3체외 제허 25-112 호
- MFDSIVD reagents for infectious disease marker(Diagnosis of Sexually transmitted disease, Legally designated infectious pathogens other than ‘high risk pathogens’, Infectious agents with moderate infectivity), molecular diagnosticsRevoked2022-06-22Product approval · Class 3체외 제허 22-407 호
- MFDSIVD reagents for cancer related gene2021-08-23Product approval · Class 3체외 제허 21-706 호
- MFDSIVD reagents for histocompatibility antigen, antibody for transfusion or transplantation, molecular diagnostics2021-06-09Product approval · Class 3체외 제허 21-461 호
- MFDSIVD reagents for histocompatibility antigen, antibody for transfusion or transplantation, molecular diagnosticsRevoked2021-05-10Product approval · Class 3체외 제허 21-361 호
- MFDSIVD reagents for cancer related gene2021-04-05Product approval · Class 3체외 제허 21-253 호
- MFDSIVD reagents for cancer related geneRevoked2021-03-02Product approval · Class 3체외 제허 21-160 호
- MFDSIVD reagents for infectious disease marker(Diagnosis of Sexually transmitted disease, Legally designated infectious pathogens other than ‘high risk pathogens’, Infectious agents with moderate infectivity), molecular diagnosticsRevoked2020-08-14Product approval · Class 3체외 제허 20-662 호
- MFDSIVD reagents for cancer related gene2020-05-28Product approval · Class 3체외 제허 20-398 호
- MFDSIVD reagents for cancer related gene2020-05-28Product approval · Class 3체외 제허 20-397 호
- MFDSIVD reagents for cancer related geneRevoked2017-12-26Product approval · Class 3체외 제허 17-983 호
Companies approved for the same productsBiotech & Drug Discovery
Ranked by how many MFDS product categories overlap. Not a ranking — a pointer to where to look.
Bioneer, founded in 1992 and KOSDAQ-listed in 2005, provides gene analysis equipment, molecular diagnostics, and RNAi drug development.
GC Medical Science Corporation, KOSDAQ-listed since 2014, operates diagnostic reagent, blood glucose, and hemodialysis solution businesses.
Founded 2011, KOSDAQ-listed 2020, Gencurix develops liquid-biopsy diagnostics: breast cancer prognosis and lung/colorectal companion tests.
Cancer molecular diagnostics company behind the EarlyTect-C stool-based colorectal cancer test using the SDC2 methylation biomarker.
Founded in 1976 and KOSDAQ-listed in 2000, HLB PANAGENE develops PNA-based molecular diagnostic and diagnostic automation products.
KOSDAQ-listed molecular genetic diagnostics company providing NGS-based non-invasive prenatal testing (NIPT) under the MomGuard brand.
Optipharm, founded in 2000 and KOSDAQ-listed in 2018, provides animal disease diagnostics, animal medicine, and biotech.
Founded 1996, listed on KOSDAQ in 2024, OSANG HEALTHCARE develops and sells biochemistry, immunodiagnostic, and molecular IVD products.
Founded in 2000 and KOSDAQ-listed in 2010, Seegene develops syndromic multiplex PCR molecular diagnostic reagents.
KOSDAQ-listed biotech company developing molecular diagnostics with proprietary C-Tag technology and the NeoPlex product line.
Supplies synthetic genes (GenOligo) and DNA sequencing analysis services for biotech research.
KOSDAQ-listed in-vitro diagnostics company developing the LabChip-based VERI-Q molecular diagnostic device series.
Sources and updates
- Company basics
- Korea Exchange · DART
- Business content
- Compiled from disclosure filings
- AI visibility
- Measured 2026-08-13
This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.
Request a correction or addition